poisar

Stocks · News reference

Barclays Maintains Equal-Weight on MarketAxess Holdings, Raises Price Target to $167

Benzinga Newsdesk

Barclays analyst Benjamin Budish maintains MarketAxess Holdings (NASDAQ:MKTX) with a Equal-Weight and raises the price target from $132 to $167.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MKTX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Brodsky & Smith

    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

    Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Personalis (acquired by Tempus AI for $16.25/share), Werewolf Therapeutics (acquired by Ambros Therapeutics), Beazer Homes (acquired by Dream Finders Homes for $33.50/share), and MarketAxess Holdings (acquired by Intercontinental Exchange for $167/share).

    PSNLHOWLBZHMKTX
  2. Zacks.Com

    Here's Why Investors Should Stay Neutral on MarketAxess Stock for Now

    MarketAxess (MKTX) is diversifying beyond U.S. credit with international expansion and new trading protocols, with non-U.S. credit revenues rising 9%. However, U.S. credit revenues declined 9%, and the stock carries an elevated forward P/E of 19.08X above industry average. The company maintains strong financials and consistent earnings beats, but faces risks from trading volume sensitivity and investment costs, warranting a neutral stance.

    MKTXMSMSPAMSPEMSPF